Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
Diabetes Mellitus, Type 2 Treated With Insulin
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 Treated With Insulin focused on measuring IDegLira, Type 2 diabetes mellitus, Glycemic, Diabetes medications.
Eligibility Criteria
Inclusion Criteria: Patients over 18 years of age with a diagnosis of type 2 diabetes mellitus who have received basal-bolus insulin during hospitalization and who, at the time of hospital discharge, are considered necessary to continue this scheme (basal-bolus). Exclusion Criteria: Patient with diagnosis or suspicion of DM1. Inability of the patient or family member to continue injectable therapy at home. CKD with GFR < 15 ml/minute by CKD EPI. History of chronic or acute pancreatitis in the last 3 months. History of personal or family history of medullary thyroid cancer. History of hypersensitivity to any of the components of the IdegLira combination. Women in pregnancy, breastfeeding or absence of hormonal contraception. Management for obesity with GLP1 receptor agonist. Previous management with basal bolus scheme with total daily dose of insulin (DDT) greater than 70 U/day. Patients with hyperglycemia associated with steroids. Patients who are insulin users prior to current hospitalization and have an in-hospital HbA1c greater than 11%.
Sites / Locations
- Hospital Universitario San IgnacioRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
basal group bolus
insulin degludec + liraglutide ( ideglira)
Insulin Glargine required on an in-hospital basis Insulin Aspart required on an in-hospital basis
16 Units once a day